Acute Myeloid Leukemia
Acute Myeloid Leukemia
The latest news, research, and perspectives in acute myeloid leukemia (AML). AML, an aggressive blood cancer, is the most common type of acute leukemia in adults and most often develops when myeloid cells that normally develop into the various types of mature blood cells instead form abnormal myeloblasts.
Advertisement
Rahul Banerjee, MD, FACPAcute Myeloid Leukemia | May 23, 2025
Experts discuss early detection in myeloid malignancies, from current challenges to future innovations.
Melissa BadamoAcute Myeloid Leukemia | May 19, 2025
ADP-heptose in the intestines of older individuals accelerates the expansion of pre-leukemic blood cells.
Melissa BadamoAcute Lymphoblastic Leukemia | May 16, 2025
Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.
Nichole TuckerAcute Myeloid Leukemia | May 27, 2025
Sankalp Arora, MBBS, a second-year fellow at MD Anderson, presented data on FLT3 inhibitors in AML at the HemOnc Pulse Live.
Andrew MorenoAcute Myeloid Leukemia | May 14, 2025
Results from the phase 1b study suggest venetoclax plus modified chemotherapy is an effective and well-tolerated approach.
Melissa BadamoAcute Myeloid Leukemia | May 13, 2025
Tuspetinib in combination with venetoclax and azacitidine showed promising clinical safety and antileukemic activity in AML.
Advertisement
Andrew MorenoAcute Myeloid Leukemia | May 9, 2025
Presented preclinical model data show significant efficacy against AML cell lines with FLT3, KMT2A, NPM1, and TP53 mutations.
Melissa BadamoAcute Lymphoblastic Leukemia | May 8, 2025
LucyRx’s pharmacy network includes Northwestern Medicine Specialty Pharmacy, Dana Farber Cancer Institute, and more..
Melissa BadamoAcute Myeloid Leukemia | May 6, 2025
Mice treated with CLK3 TCR9-T cells had a significantly lower tumor burden than those who received control treatments.
Kelly S. Chien, MDAcute Myeloid Leukemia | May 6, 2025
Kelly Chien, MD, discusses how disparities in access to care, resources, and molecular testing impact outcomes in AML.
Melissa BadamoAcute Myeloid Leukemia | April 29, 2025
CR1-02 was well-tolerated and led to stable disease in patients with relapsed or refractory AML.
Andrew MorenoTransplantation & Cellular Therapy | April 25, 2025
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
Melissa BadamoAcute Lymphoblastic Leukemia | April 23, 2025
The Community Oncology Alliance outlined solutions for Congress to address systemic challenges of the U.S. healthcare system.
Andrew MorenoAcute Myeloid Leukemia | April 22, 2025
The investigational small molecule enzomenib has received FDA Orphan Drug and Fast Track designations in AML.
Melissa BadamoAcute Myeloid Leukemia | April 17, 2025
GPC-100 is a a small molecule CXCR4 inhibitor that showed promising preclinical activity in combination with cytarabine.
Melissa BadamoPrint | April 14, 2025
The award provides early-career researchers at NCCN Member Institutions with $150,000 in funding to support cancer research.
Melissa BadamoVideo Insights | April 15, 2025
Nicholas Freedman, DO, presented on symptom management and supportive care at the Tri-State Blood Cancer Conference.
Melissa BadamoAcute Lymphoblastic Leukemia | April 8, 2025
More than 240 meetings were held with members of Congress as part of the ASCO 10th Annual Advocacy Summit.
Nichole TuckerAcute Lymphoblastic Leukemia | April 15, 2025
Joseph G. Jurcic, MD on the journey to survivorship for adults with either AML or ALL.
Andrew MorenoMyelodysplastic Syndromes | April 2, 2025
This agent which has newly received an ODD for MDS recalibrates the immune system to attack hematological and solid tumors.
Advertisement
Advertisement